Australia could miss the WHO hepatitis C virus elimination targets due to declining treatment uptake and ongoing burden of advanced liver disease complications

Australia was one of the first countries to introduce government-funded unrestricted access to direct-acting antiviral (DAA) therapy, with 88,790 treated since March 2016. However, treatment uptake is declining which could potentially undermine Australia’s progress towards the WHO HCV elimination ta...

Descripción completa

Detalles Bibliográficos
Autores principales: Kwon, Jisoo A., Dore, Gregory J., Hajarizadeh, Behzad, Alavi, Maryam, Valerio, Heather, Grebely, Jason, Guy, Rebecca, Gray, Richard T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8445464/
https://www.ncbi.nlm.nih.gov/pubmed/34529711
http://dx.doi.org/10.1371/journal.pone.0257369

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8445464/
https://www.ncbi.nlm.nih.gov/pubmed/34529711
http://dx.doi.org/10.1371/journal.pone.0257369

Ejemplares similares